1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study [0.03%]
在2型糖尿病患者中评估肥胖人群使用司美格鲁肽、 tirzepatide 和袖状胃切除术的1年结局：一项回顾性队列研究
Daniel B Leslie,Brian T Steffen,Eric Wise et al.
Daniel B Leslie et al.
Background: Type 2 diabetes and obesity are prevalent, inter-related conditions for which treatment options have expanded substantially, yet direct real-world comparisons of modern pharmacological and surgical interventio...
Benjamin Z Leder,Sabashini K Ramchand,Hang Lee et al.
Benjamin Z Leder et al.
Michael R McClung,David Dempster,Felicia Cosman
Michael R McClung
Early-stage type 1 diabetes: is there a role for lifestyle modifications? [0.03%]
1型糖尿病早期：生活方式的调整有用吗？
Theodora Papanikolaou,Rob C Andrews,Emma Cockcroft et al.
Theodora Papanikolaou et al.
A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular prevention [0.03%]
血脂医学的创新改变了心血管预防：二十五年的进展
Lluís Masana,Josep Ribalta,Daiana Ibarretxe
Lluís Masana
This TimeCapsule reviews the major transformations in lipid metabolism and cardiovascular disease prevention during the first quarter of the 21st century and their impact on clinical practice. From late 20th century paradigms to current sta...
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study [0.03%]
一项在饮食和运动控制不佳的2型糖尿病成人中评估一周一次卡格利汀肽-索马鲁肽(CagriSema)疗效和安全性的3a期随机、双盲、安慰剂对照试验（REIMAGINE 1）
Vanita R Aroda,Raffaella Buzzetti,Stine-Mathilde Dalskov et al.
Vanita R Aroda et al.
Background: Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide. We aimed to assess the efficacy and safety of ca...